• 简

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Stryker (SYK) Could Be 15% Below Fair Value As Mako RPS Launch Draws Focus

    Simply Wall St·07/26/2026 00:33:12
    语音播报

    Stryker (SYK) is drawing fresh attention after launching its Mako RPS handheld robotic system in the U.S. for total knee replacements, extending the Mako portfolio beyond traditional robotic arm platforms.

    See our latest analysis for Stryker.

    The Mako RPS launch comes as Stryker’s share price has recently picked up, with a 1 day share price return of 3.54% and a 30 day share price return of 5.28%, even though the year to date share price return is down 5.15% and the 1 year total shareholder return is down 17.33%. The 3 year and 5 year total shareholder returns of 20.16% and 28.39% point to stronger longer term compounding.

    If this kind of robotics story has your attention, it could be a good moment to see what else is shaping the sector through our 34 robotics and automation stocks

    Stryker’s shares now sit at a meaningful discount to both the stated fair value estimate and analyst targets after the Mako RPS driven bump. Is the market sensibly cautious, or too slow to reprice the story?

    Most Popular Narrative: 15% Undervalued

    The most followed narrative currently values Stryker at $386.80 per share, versus the last close of $330.25, framing the recent Mako RPS excitement within a broader long term thesis.

    Robust innovation pipeline, particularly in robotic-assisted surgery (Mako platform) and next-generation devices, is driving greater market share, higher average selling prices, and service revenues, which is expected to accelerate both revenue and margin expansion over time.

    Read the complete narrative.

    Want to see what underpins that higher fair value for Stryker? The narrative leans on steady revenue gains, rising margins, and a richer earnings multiple. The exact mix of those drivers might surprise you.

    Result: Fair Value of $386.80 (UNDERVALUED)

    Have a read of the narrative in full and understand what's behind the forecasts.

    However, Stryker’s story could change quickly if prolonged regulatory delays in Europe or ongoing supply chain disruptions start to bite harder than analysts currently model.

    Find out about the key risks to this Stryker narrative.

    Another View: What Stryker’s P/E Is Saying

    The DCF work suggests Stryker is undervalued, yet the current P/E of 37.9x sits well above the US Medical Equipment industry at 26.7x, the peer average at 28x, and even the 34.6x fair ratio estimate. That premium could signal quality, or it could mean less room for error.

    Before leaning on any single approach, it is worth stress testing the DCF assumptions and comparing them to other scenarios in the SWS DCF model, especially if growth or margins end up tracking differently to consensus Look into how the SWS DCF model arrives at its fair value.

    SYK Discounted Cash Flow as at Jul 2026
    SYK Discounted Cash Flow as at Jul 2026

    Next Steps

    If the mix of optimism and concern around Stryker feels finely balanced, take a closer look at the data now and shape your own view with the 3 key rewards and 2 important warning signs

    Looking for more investment ideas beyond Stryker?

    If Stryker has sharpened your interest, do not stop here. Broaden your watchlist with other stocks that fit clear, data backed themes using the Simply Wall Street Screener.

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.